Sangui BioTech GmbH press releases:
Sangui BioTech:
- Mölnlycke launches large multi-center study of Granulox.
Hamburg, December, 04, 2019:
Mölnlycke Health Care A/B the parent company of Sastomed GmbH, to which Sangui licensed the wound spray Granulox launches a large multi-center study of Granulox. The study will be conducted in multiple centers in France, Germany, UK, Poland, Croatia and Czech Republic and will focus on leg ulcers and their resp. treatment. 254 patients will be randomized to either standard of care group or standard of care with Granulox added as an adjunct therapy in predominantly venous leg ulcer subjects. The duration of the study will be 20 weeks for any given patient. The results of the study are expected by the end of 2022.
For details, please check with the following link:
https://clinicaltrials.gov/ct2/show/NCT04181320
Sangui BioTech International, Inc. ("SGBI") is a holding company the shares of which are being traded on the OTCQB venture stage marketplace for early stage and developing U.S. and international companies (OTCQB: SGBI). Companies are current in their reporting and undergo an annual verification and management certification process. Sangui shares also trade on the OTC markets of Berlin and Hamburg-Hannover stock exchanges (symbol: SBH). Its purpose is to provide financing and access to the capital markets for the enterprises of the Sangui group. SanguiBioTech GmbH is a ninety percent subsidiary of Sangui BioTech International, Inc.
For more information please contact:
Sangui Biotech International, Inc.
Thomas Striepe
Fax: +49 (2302) 915191
e-mail: info@sangui.de
Some of the statements contained in this news release discuss future expectations, contain projections of results of operation or financial condition or state other “forward-looking” information. These statements are subject to known and unknown risks, uncertainties, and other factors that could cause the actual results to differ materially from those contemplated by the statements. The forward-looking information is based on various factors and is derived using numerous assumptions. Important factors that may cause actual results to differ from projections include, among many others, the ability of the Company to raise sufficient capital to meet operating requirements. Words such as “anticipates,” “expects,” “intends,” “plans,” “believes,” “seeks,” “estimates,” and variations of such words and similar expressions are intended to identify such forward-looking statements. Unless required by law, the Company undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.
Sangui BioTech:
- Significant cost reductions in the first quarter
- Mölnlycke invests in warehouse capacities
Hamburg, November, 15 2019:
In the first three months of fiscal year 2020 (to 30/06/2020) Sangui BioTech International Inc. achieved revenues from royalty income of USD 282. In the same period of the previous year the comparable revenue amounted to USD 11,272. Due to lower revenues of the wound spray Granulox, the resulting royalty income in the first three month of the year was significantly below the level of the same period of the previous year.
Responsible for this development were measures for the integration of the licensee, SastoMed GmbH into the Mölnlycke Group. In particular, the restructuring of the sales and distribution channels in the Mölnlycke Group has taken some time. Necessary investments in new warehouse capability to meet future demands have meanwhile been completed. Mölnlycke believes that these measures will bear fruit with respect to revenue.
As operating expenses decreased USD 48,517 or 46% to USD 56,180 during the period, three month operating loss decreased USD 37,600 to USD 55,898 from the prior year. The reason for this was cost savings in connection with the closure of the Witten site.
Sangui BioTech International, Inc. ("SGBI") is a holding company the shares of which are being traded on the OTCQB venture stage marketplace for early stage and developing U.S. and international companies (OTCQB: SGBI). Companies are current in their reporting and undergo an annual verification and management certification process. Sangui shares also trade on the OTC markets of Berlin and Hamburg-Hannover stock exchanges (symbol: SBH). Its purpose is to provide financing and access to the capital markets for the enterprises of the Sangui group. SanguiBioTech GmbH is a ninety percent subsidiary of Sangui BioTech International, Inc.
For more information please contact:
Sangui Biotech International, Inc.
Thomas Striepe
Fax: +49 (2302) 915191
e-mail: info@sangui.de
Some of the statements contained in this news release discuss future expectations, contain projections of results of operation or financial condition or state other “forward-looking” information. These statements are subject to known and unknown risks, uncertainties, and other factors that could cause the actual results to differ materially from those contemplated by the statements. The forward-looking information is based on various factors and is derived using numerous assumptions. Important factors that may cause actual results to differ from projections include, among many others, the ability of the Company to raise sufficient capital to meet operating requirements. Words such as “anticipates,” “expects,” “intends,” “plans,” “believes,” “seeks,” “estimates,” and variations of such words and similar expressions are intended to identify such forward-looking statements. Unless required by law, the Company undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.
PDF Download